The topic of pheochromocytomas is becoming increasingly popular as a result of major advances in different medical fields, including laboratory diagnosis, genetics, therapy, and particularly in novel advances in imaging techniques. The present review article discusses current clinical, biochemical, genetic and histopathological aspects of the diagnosis of pheochromocytomas and planning of pre-surgical preparation and subsequent surgical treatment options. The main part of the paper is focused on the role of morphological imaging methods (primarily computed tomography and magnetic resonance imaging) and functional imaging (scintigraphy and positron emission tomography) in the diagnosis and staging of pheochromocytomas.

Department of Clinical and Molecular Pathology University Hospital and Faculty of Medicine and Dentistry Palacky University 779 00 Olomouc Czech Republic

Department of Internal Medicine 3 Nephrology Rheumatology and Endocrinology University Hospital and Faculty of Medicine and Dentistry Palacky University 779 00 Olomouc Czech Republic

Department of Nuclear Medicine University Hospital and Faculty of Medicine and Dentistry Palacky University 779 00 Olomouc Czech Republic

Department of Radiology University Hospital and Faculty of Medicine and Dentistry Palacky University 779 00 Olomouc Czech Republic

Department of Urology University Hospital and Faculty of Medicine and Dentistry Palacky University 779 00 Olomouc Czech Republic

Zobrazit více v PubMed

Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity. Nat Rev Cancer. 2014;14:108–119. doi: 10.1038/nrc3648. PubMed DOI

Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665–675. doi: 10.1016/S0140-6736(05)67139-5. PubMed DOI

Lam AK. Update on adrenal tumours in 2017 world health organization (WHO) of endocrine tumours. Endocr Pathol. 2017;28:213–227. doi: 10.1007/s12022-017-9484-5. PubMed DOI

Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th. IACR; Lyon: 2017.

Roman-Gonzalez A, Jimenez C. Malignant pheochromocytoma-paraganglioma: Pathogenesis, TNM staging and current clinical trials. Curr Opin Endocrinol Diabetes Obes. 2017;24:174–183. doi: 10.1097/MED.0000000000000330. PubMed DOI

Amin B, Edge S, Greene F. AJCC cancer staging manual. Springer; New York: 2017. DOI

Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF, Jr, Endocrine Society Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–1942. doi: 10.1210/jc.2014-1498. PubMed DOI

Crona J, Taïeb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: Towards a molecular classification. Endocr Rev. 2017;38:489–515. doi: 10.1210/er.2017-00062. PubMed DOI PMC

Pacak K, Del Rivero J. In: Pheochromocytoma (Updated June 10, 2013) Endotext. De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, et al., editors. MDText.com, Inc.; South Dartmouth, MA: 2000.

Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459–1466. doi: 10.1056/NEJMoa020152. PubMed DOI

Pacak K, Wimalawansa SJ. Pheochromocytoma and paraganglioma. Endocr Pract. 2015;21:406–412. doi: 10.4158/EP14481.RA. PubMed DOI

Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42:229–233. doi: 10.1038/ng.533. PubMed DOI PMC

Tsirlin A, Oo Y, Sharma R, Kansara A, Gliwa A, Banerji MA. Pheochromocytoma: A review. Maturitas. 2014;77:229–238. doi: 10.1016/j.maturitas.2013.12.009. PubMed DOI

Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848–851. doi: 10.1126/science.287.5454.848. PubMed DOI

Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268–270. doi: 10.1038/81551. PubMed DOI

Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Sköldberg F, Husebye ES, Eng C, Maher ER. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69:49–54. doi: 10.1086/321282. PubMed DOI PMC

Karasek D, Shah U, Frysak Z, Stratakis C, Pacak K. An update on the genetics of pheochromocytoma. J Hum Hypertens. 2013;27:141–147. doi: 10.1038/jhh.2012.20. PubMed DOI PMC

Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: Implications for genetic testing. J Clin Endocrinol Metab. 2006;91:4505–4509. doi: 10.1210/jc.2006-0423. PubMed DOI

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31:181–193. doi: 10.1016/j.ccell.2017.01.001. PubMed DOI PMC

NGS, in PPGL (NGSnPPGL) Study Group. Toledo RA, Burnichon N, Cascon A, Benn DE, Bayley JP, Welander J, Tops CM, Firth H, Dwight T, et al. Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 2017;13:233–247. doi: 10.1038/nrendo.2016.185. PubMed DOI

Zelinka T, Widimský J. Pheochromocytoma-why is its early diagnosis so important for patient? Vnitr Lek. 2015;61:487–491. PubMed

Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315–329. doi: 10.7326/0003-4819-134-4-200102200-00016. PubMed DOI

Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K, North American Neuroendocrine Tumor Society (NANETS) The North American neuroendocrine tumor society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma and medullary thyroid cancer. Pancreas. 2010;39:775–783. doi: 10.1097/MPA.0b013e3181ebb4f0. PubMed DOI PMC

Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: Which test is best? JAMA. 2002;287:1427–1434. doi: 10.1001/jama.287.11.1427. PubMed DOI

Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res. 2008;40:329–337. doi: 10.1055/s-2008-1073156. PubMed DOI PMC

Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K. Biochemical diagnosis of pheochromocytoma: How to distinguish true-from false-positive test results. J Clin Endocrinol Metab. 2003;88:2656–2666. doi: 10.1210/jc.2002-030005. PubMed DOI

Jacques AE, Sahdev A, Sandrasagara M, Goldstein R, Berney D, Rockall AG, Chew S, Reznek RH. Adrenal phaeochromocytoma: Correlation of MRI appearances with histology and function. Eur Radiol. 2008;18:2885–2892. doi: 10.1007/s00330-008-1073-z. PubMed DOI

Motta-Ramirez GA, Remer EM, Herts BR, Gill IS, Hamrahian AH. Comparison of CT Findings in symptomatic and incidentally discovered pheochromocytomas. Am J Roentgenol. 2005;185:684–688. doi: 10.2214/ajr.185.3.01850684. PubMed DOI

Čtvrtlík F, Heřman M, Študent V, Tichá V, Minařík J. Differential diagnosis of incidentally detected adrenal masses revealed on routine abdominal CT. Eur J Radiol. 2009;69:243–252. doi: 10.1016/j.ejrad.2007.11.041. PubMed DOI

Patel J, Davenport MS, Cohan RH, Caoili EM. Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma? AJR Am J Roentgenol. 2013;201:122–127. doi: 10.2214/AJR.12.9620. PubMed DOI

Schieda N, Alrashed A, Flood TA, Samji K, Shabana W, McInnes MD. Comparison of quantitative MRI and CT washout analysis for differentiation of adrenal pheochromocytoma from adrenal adenoma. AJR Am J Roentgenol. 2016;206:1141–1148. doi: 10.2214/AJR.15.15318. PubMed DOI

Zhang GM, Shi B, Sun H, Jin ZY, Xue HD. Differentiating pheochromocytoma from lipid-poor adrenocortical adenoma by CT texture analysis: Feasibility study. Abdom Radiol. 2017;42:2305–2313. doi: 10.1007/s00261-017-1118-3. PubMed DOI

McDermott S, McCarthy CJ, Blake MA. Images of pheochromocytoma in adrenal glands. Gland Surg. 2015;4:350–358. PubMed PMC

Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, Eisenhofer G. A ‘pheo’ lurks: Novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab. 2001;86:3641–3646. doi: 10.1210/jc.86.8.3641. PubMed DOI

Korobkin M, Giordano TJ, Brodeur FJ, Francis IR, Siegelman ES, Quint LE, Dunnick NR, Heiken JP, Wang HH. Adrenal adenomas: Relationship between histologic lipid and CT and MR findings. Radiology. 1996;200:743–747. doi: 10.1148/radiology.200.3.8756925. PubMed DOI

Remer EM, Motta-Ramirez GA, Shepardson LB, Hamrahian AH, Herts BR. CT histogram analysis in pathologically proven adrenal masses. Am J Roentgenol. 2006;187:191–196. doi: 10.2214/AJR.05.0179. PubMed DOI

Lubner MG, Smith AD, Sandrasegaran K, Sahani DV, Pickhardt PJ. CT texture analysis: Definitions, applications, biologic correlates and challenges. RadioGraphics. 2017;37:1483–1503. doi: 10.1148/rg.2017170056. PubMed DOI

Northcutt BG, Raman SP, Long C, Oshmyansky AR, Siegelman SS, Fishman EK, Johnson PT. MDCT of adrenal masses: Can dual-phase enhancement patterns be used to differentiate adenoma and pheochromocytoma? AJR Am J Roentgenol. 2013;201:834–839. doi: 10.2214/AJR.12.9753. PubMed DOI

Korobkin M, Brodeur FJ, Yutzy GG, Francis IR, Quint LE, Dunnick NR, Kazerooni EA. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol. 1996;166:531–536. doi: 10.2214/ajr.166.3.8623622. PubMed DOI

Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol. 2000;175:1411–1415. doi: 10.2214/ajr.175.5.1751411. PubMed DOI

Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, Schoellnast H, Preidler KW, Samonigg H. Adrenocortical carcinomas and adrenal pheochromocytomas: Mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234:479–485. doi: 10.1148/radiol.2342031876. PubMed DOI

Kumagae Y, Fukukura Y, Takumi K, Shindo T, Tateyama A, Kamiyama T, Kamimura K, Nakajo M. Distinguishing adrenal adenomas from non-adenomas on dynamic enhanced CT: A comparison of 5 and 10 min delays after intravenous contrast medium injection. Clin Radiol. 2013;68:696–703. doi: 10.1016/j.crad.2013.01.016. PubMed DOI

Mukherjee JJ, Peppercorn PD, Reznek RH, Patel V, Kaltsas G, Besser M, Grossman AB. Pheochromocytoma: Effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology. 1997;202:227–231. doi: 10.1148/radiology.202.1.8988215. PubMed DOI

Bessell-Browne R, O'Malley ME. CT of pheochromocytoma and paraganglioma: Risk of adverse events with i.v. administration of nonionic contrast material. AJR Am J Roentgenol. 2007;188:970–974. doi: 10.2214/AJR.06.0827. PubMed DOI

Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: Update in diagnosis and management. Endocr Rev. 2004;25:309–340. doi: 10.1210/er.2002-0031. PubMed DOI

Tsushima Y, Takahashi-Taketomi A, Endo K. Diagnostic utility of diffusion-weighted MR imaging and apparent diffusion coefficient value for the diagnosis of adrenal tumors. J Magn Reson Imaging. 2009;29:112–117. doi: 10.1002/jmri.21616. PubMed DOI

Umanodan T, Fukukura Y, Kumagae Y, Shindo T, Nakajo M, Takumi K, Nakajo M, Hakamada H, Umanodan A, Yoshiura T. ADC histogram analysis for adrenal tumor histogram analysis of apparent diffusion coefficient in differentiating adrenal adenoma from pheochromocytoma. J Magn Reson Imaging. 2017;45:1195–1203. doi: 10.1002/jmri.25452. PubMed DOI

Dong Y, Liu Q. Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T. J Comput Assist Tomogr. 2012;36:361–366. doi: 10.1097/RCT.0b013e31825975f8. PubMed DOI

Kim S, Salibi N, Hardie AD, Xu J, Lim RP, Lee VS, Taouli B. Characterization of adrenal pheochromocytoma using respiratory-triggered proton MR spectroscopy: Initial experience. AJR Am J Roentgenol. 2009;192:450–454. doi: 10.2214/AJR.07.4027. PubMed DOI

Melo HJ, Goldman SM, Szejnfeld J, Faria JF, Huayllas MK, Andreoni C, Kater CE. Application of a protocol for magnetic resonance spectroscopy of adrenal glands: An experiment with over 100 cases. Radiol Bras. 2014;47:333–341. doi: 10.1590/0100-3984.2013.1812. PubMed DOI PMC

Reimer P, Parizel PM, Stichnoth FA. Clinical MR imaging: A practical approach Second, completely revised and updated. Springer-Verlag; Berlin Heidelberg New York: 2006. DOI

Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging. 1999;10:477–484. doi: 10.1002/(SICI)1522-2586(199909)10:3<477::AID-JMRI33>3.0.CO;2-E. PubMed DOI

Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, Opocher G, de Herder WW, Boedeker CC, de Krijger RR. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1977–1995. doi: 10.1007/s00259-012-2215-8. PubMed DOI PMC

Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, Moncayo R, Mortelmans L, Pepe G, Reske SN, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–2446. doi: 10.1007/s00259-010-1545-7. PubMed DOI

Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, Rufini V, Giordano A. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: A meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39:1144–1153. doi: 10.1007/s00259-012-2087-y. PubMed DOI

Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, et al. 6-(F-18)Fluoro-l-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922–3930. doi: 10.1210/jc.2009-1054. PubMed DOI

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT, Pacak K. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104:700–708. doi: 10.1093/jnci/djs188. PubMed DOI PMC

Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, Adams KT, Wolf KI, Herscovitch P, Fojo AT, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43:1784–1791. doi: 10.1007/s00259-016-3357-x. PubMed DOI PMC

Jing H, Li F, Wang L, Wang Z, Li W, Huo L, Zhang J. Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT and MIBG SPECT/CT in the evaluation of suspected primary pheochromocytomas and paragangliomas. Clin Nucl Med. 2017;42:525–529. doi: 10.1097/RLU.0000000000001674. PubMed DOI

Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, Hicks RJ, Hofman MS. 68Ga-DOTATATE and 18F-FDG PET/CT in paraganglioma and pheochromocytoma: Utility, patterns and heterogeneity. Cancer Imaging. 2016;16 doi: 10.1186/s40644-016-0084-2. PubMed DOI PMC

Tato A, Orte L, Diz P, Quereda C, Ortuno J. Malignant pheochromocytoma, still a therapeutic challenge. Am J Hypertens. 1997;10:479–481. doi: 10.1016/S0895-7061(97)00064-2. PubMed DOI

Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA. Prognostic indicators of malignancy in adrenal pheochromocytomas: Clinical, histopathologic and cell cycle/apoptosis gene expression analysis. Surgery. 2008;143:759–768. doi: 10.1016/j.surg.2008.02.007. PubMed DOI

Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26:551–566. doi: 10.1097/00000478-200205000-00002. PubMed DOI

Mlika M, Kourda N, Zorgati MM, Bahri S, Ben Ammar S, Zermani R. Prognostic value of Pheochromocytoma of the adrenal gland scaled score (Pass score) tests to separate benign from malignant neoplasms. Tunis Med. 2013;91:209–215. PubMed

de Wailly P, Oragano L, Radé F, Beaulieu A, Arnault V, Levillain P, Kraimps JL. Malignant pheochromocytoma: New malignancy criteria. Langenbecks Arch Surg. 2012;397:239–246. doi: 10.1007/s00423-011-0850-3. PubMed DOI

Duregon E, Volante M, Bollito E, Goia M, Buttigliero C, Zaggia B, Berruti A, Scagliotti GV, Papotti M. Pitfalls in the diagnosis of adrenocortical tumors: A lesson from 300 consultation cases. Hum Pathol. 2015;46:1799–1807. doi: 10.1016/j.humpath.2015.08.012. PubMed DOI

Ctvrtlik F, Koranda P, Tichy T. Adrenal disease: A clinical update and overview of imaging. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158:23–34. PubMed

Hodin R, Lubitz C, Phitayakorn R, Stephen A. Diagnosis and management of pheochromocytoma. Curr Probl Surg. 2014;51:151–187. doi: 10.1067/j.cpsurg.2013.12.001. PubMed DOI

Vanderveen KA, Thompson SM, Callstrom MR, Young WF, Jr, Grant CS, Farley DR, Richards ML, Thompson GB. Biopsy of pheochromocytomas and paragangliomas: Potential for disaster. Surgery. 2009;146:1158–1166. doi: 10.1016/j.surg.2009.09.013. PubMed DOI

Brunaud L, Nguyen-Thi PL, Mirallie E, Raffaelli M, Vriens M, Theveniaud PE, Boutami M, Finnerty BM, Vorselaars WM, Rinkes IB, et al. Predictive factors for postoperative morbidity after laparoscopic adrenalectomy for pheochromocytoma: A multicenter retrospective analysis in 225 patients. Surg Endosc. 2015;30:1051–1059. doi: 10.1007/s00464-015-4294-7. PubMed DOI

Perel Y, Schlumberger M, Marguerite G, Alos N, Revillon Y, Sommelet D, De Lumley L, Flamant F, Dyon JF, Lutz P, et al. Pheochromocytoma and paraganglioma in children: A report of 24 cases of the french society of pediatric oncology. Pediatr Hematol Oncol. 1997;14:413–422. doi: 10.3109/08880019709028771. PubMed DOI

Wang W, Li P, Wang Y, Wang Y, Ma Z, Wang G, Gao J, Zhou H. Effectiveness and safety of laparoscopic adrenalectomy of large pheochromocytoma: A prospective, nonrandomized, controlled study. Am J Surg. 2015;210:230–235. doi: 10.1016/j.amjsurg.2014.11.012. PubMed DOI

Diagnostic Value of Unenhanced CT Attenuation and CT Histogram Analysis in Differential Diagnosis of Adrenal Tumors